The ACC and Pfizer are collaborating to offer a new grant opportunity, seeking proposals for quality improvement initiatives that will increase identification and accurate diagnosis of heart failure (HF) patients with transthyretin amyloid cardiomyopathy (ATTR-CM). Learn more and apply by May 28.